Table 2 Clinical outcomes at one year after transplantation.

From: Effect of simultaneous presence of anti-blood group A/B and -HLA antibodies on clinical outcomes in kidney transplantation across positive crossmatch: a nationwide cohort study

 

aABOc/XM+

aABOi/XM+

P-value

Number of patients, XM+

176 (66.9)

87 (33.1)

 

Overall rejection

21 (11.7)

25 (25.5)

<0.01

ACR only

5 (2.8)

6 (6.1)

0.17

AMR with or without ACR

16 (8.9)

19 (19.4)

0.01

Number of patients, CDC+

14 (63.6)

8 (36.4)

 

Overall rejection

0 (0.0)

5 (62.5)

<0.01

ACR only

0 (0.0)

0 (0.0)

—

AMR with or without ACR

0 (0.0)

5 (62.5)

<0.01

Number of patients, FCXM+

162 (67.2)

79 (32.8)

 

Overall rejection

21 (13.0)

17 (21.5)

0.09

ACR only

5 (3.1)

4 (5.1)

0.48

AMR with or without ACR

16 (9.9)

13 (16.5)

0.14

Mortality

0 (0.0)

4 (4.6)

<0.01

Bacterial infection

  

0.14

Urinary tract infection

39 (21.7)

12 (12.1)

 

Pneumonia

14 (7.8)

7 (7.1)

 

Biopsy proven BKVN

1 (0.6)

1 (1.1)

0.61

Surgical complications

  

0.30

Bleeding

10 (5.6)

2 (2.0)

 

Urinary complications

3 (1.7)

3 (3.1)

 
  1. Values are presented as numbers of patients (%).
  2. Abbreviations: ACR, acute cellular rejection; AMR, Acute antibody-mediated rejection; CDC, complement-dependent cytotoxicity; FCXM, flow-cytometric crossmatch; BKVN, BK virus nephropathy.
  3. aCrossmatch-positive (XM+) defined as FCXM-positive and CDC XM-positive; ABOc, ABO compatible; ABOi, ABO incompatible.
Back to article page